Turn Therapeutics Inc.
TTRX
$3.98
$0.102.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.00% | 34.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 40.60% | 40.04% | |||
| Operating Income | -40.60% | -40.04% | |||
| Income Before Tax | 114.66% | -53.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 114.66% | -53.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 114.66% | -53.51% | |||
| EBIT | -40.60% | -40.04% | |||
| EBITDA | -40.87% | -40.31% | |||
| EPS Basic | 114.39% | -51.00% | |||
| Normalized Basic EPS | 114.35% | -50.71% | |||
| EPS Diluted | 114.39% | -51.00% | |||
| Normalized Diluted EPS | 114.35% | -50.71% | |||
| Average Basic Shares Outstanding | 1.61% | 1.77% | |||
| Average Diluted Shares Outstanding | 1.61% | 1.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||